A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

Recruiting

Phase 2

Phase 3

Cabozantinib & MAPA Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

Sponsor:

National Cancer Institute (NCI)

Code:

NCT05691478

Conditions

High Grade Osteosarcoma

Localized Osteosarcoma

Metastatic Osteosarcoma

Secondary Osteosarcoma

Eligibility Criteria

Sex: All

Age: 0 - 40

Healthy Volunteers: Not accepted

Interventions

Bone Scan

Cabozantinib S-malate

Cisplatin

Computed Tomography

Doxorubicin Hydrochloride

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-18. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2025-09-17.